cialis farmaco generico levitra en pharmacie kamagra amsterdam comprar viagra barata köp viagra i sverige viagra genericos acheter viagra au quebec cialis lääke cialis 20 mg precio levitra precios prix viagra officiel france cialis se vende con receta viagra generico opinioni avis viagra internet vendo viagra santiago

Chicago ENT head and neck surgeons using VELscope Vx to enhance oral cancer surgery success rate

Thu, Jan 10, 2013

Oral Cancer News

Source: www.menafn.com
Author: press release

LED Medical Diagnostics Inc. subsidiary LEDDental announced today that its VELscope Vx enhanced oral assessmentdevice will now be used by Chicago Otolaryngology Associates for oralmucosal abnormality assessment and when performing surgery on oral cancer patients.

According to Chicago Otolaryngology Associates’ Howard Kotler, MD,FACS, “We pride ourselves on embracing state-of-the-art technologies that allow us to provide the best patient care possible. The VELscopeVx may significantly enhance our ability to see the entire cancerous or precancerous lesion that needs to be excised, allowing us to minimize risk of additional unnecessary surgery.”

The VELscope Vx’s fluorescence visualization technology is the first approved by the FDA and Health Canada to help surgeons determine the surgical margins when excising cancerous and precancerous tissues. The technology is also approved to help dental and medical professionals discover cancerous and precancerous tissue that might not be apparent to the unaided eye.

The vast majority of the nearly 12,000 VELscope devices in use around the world are used by dental practices. Typically, when a suspicious lesion is detected by a dentist, the patient is referred to an oral surgeon or a periodontist for a surgical biopsy, which is then evaluated by an oral pathologist. If the biopsy sample is determined to be cancerous or precancerous, the patient is usually referred to an ENT head and neck surgeon for consultation and likely excision. VELscope technology was developed to address the problem of detecting all abnormal tissue, including that beneath the surface, as well as making it possible for dentists to discover early stage oral cancer, which requires less invasive treatment and has a significantly higher chance of survival than when the disease is detected in late stages.

“We applaud Dr. Kotler and Chicago Otolaryngology Associates forbeing one of the first Otolaryngology practices in the U.S. toincorporate VELscope’s potentially life-saving technology,” saidPeter Whitehead, founder and CEO of LED Dental and its parent, LEDMedical Diagnostics Inc. .

Print Friendly
Be Sociable, Share!
, , , , ,

Leave a Reply

You must be logged in to post a comment.